SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Roche Holding AG (RHHVF) trades at a trailing P/E of 25.1, forward P/E of 19.9. Trailing earnings yield is 3.98%, forward earnings yield 5.04%. PEG 0.45 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (60/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.45).
- Forward P/E 19.9 (down from trailing 25.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.45 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.98% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.04% as earnings recover.
Overall SharesGrow Score: 67/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RHHVF
Valuation Multiples
P/E (TTM)25.1
Forward P/E19.9
PEG Ratio0.45
Forward PEG0.75
P/B Ratio0.00
P/S Ratio5.26
EV/EBITDA0.0
Per Share Data
EPS (TTM)$16.05
Forward EPS (Est.)$20.32
Book Value / Share$0.00
Revenue / Share$76.64
FCF / Share$0.00
Yields & Fair Value
Earnings Yield3.98%
Forward Earnings Yield5.04%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$11.13 |
$50.58B |
$9.58B |
18.9% |
| 2017 |
$10.04 |
$53.3B |
$8.63B |
16.2% |
| 2018 |
$12.21 |
$56.85B |
$10.5B |
18.5% |
| 2019 |
$15.62 |
$61.47B |
$13.5B |
22% |
| 2020 |
$16.52 |
$58.32B |
$14.3B |
24.5% |
| 2021 |
$16.20 |
$62.8B |
$13.93B |
22.2% |
| 2022 |
$15.53 |
$63.28B |
$12.42B |
19.6% |
| 2023 |
$14.30 |
$60.44B |
$11.5B |
19% |
| 2024 |
$10.32 |
$62.4B |
$8.28B |
13.3% |
| 2025 |
$16.05 |
$61.55B |
$12.89B |
20.9% |
